Navigation Links
Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
Date:11/6/2008

er cancer patients has been initiated that will test immediate post operative (IPOP) intravesical administration of Chemophase, the combination of rHuPH20 with mitomycin C immediately following transurethral resection of bladder tumor (TURBT). Results of this small safety study will be used to support the inclusion of the IPOP dosing regimen as part of the protocol in future Chemophase studies. Halozyme is making preparations to meet with regulatory authorities during the first half of 2009 to discuss the trial design for potential registration studies.

-- Halozyme hosted its first Research Day for financial analysts and the investment community on October 6, 2008 in New York. The well attended event provided a forum for an in depth presentation and discussion by the Halozyme management team of its proprietary product development pipeline, its plans for future clinical trials, and its business strategy. A replay of the meeting can be found on the Halozyme website. (http://phx.corporate-ir.net/phoenix.zhtml?c=175436&p=irol-calendar)

-- The company has recently strengthened its senior management team with the addition of Douglas B. Muchmore, M.D., Vice President, Endocrinology Clinical Development, Patrick O'Connor, Ph.D., Vice President, Research, Michael J. LaBarre, Ph.D., Vice President, Product Development, and James E. Cartoni, Vice President, Legal. Successfully recruiting, developing, and retaining high caliber, experienced executives exemplifies Halozyme's commitment to exceptional talent.

-- Positive pre-clinical animal efficacy data (http://www.halozyme.com/2008AACRTCsk-4%20-%20large.pdf)were presented for PEGPH20 at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, Calif. on July 21, 2008. The study demonstrat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics to Host Research Day for Investors and Analysts
5. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
7. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
9. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... Inc. (NASDAQ: GNVC ) today announced the retirement ... of directors effective on October 24, 2014.   Dr. Horovitz joined ... chairman from June 2006 to November 2013.  During his tenure, ... Audit Committees of the board.  "We deeply ... to GenVec, and its stockholders," said Wayne T. Hockmeyer ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... June 30 Celsis In Vitro, Inc. (Celsis ... infringement lawsuit against Invitrogen Corporation (Invitrogen) and CellzDirect, Inc. ... Northern District of Illinois in Chicago ... the parent of CellzDirect, is itself a wholly-owned subsidiary ...
... showcasing pharmaceutical, biotechnological and medical device employers in areas ranging from Niagara Falls to ... (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading employment Web site for the life sciences launched the ...
... TargeGen, Inc., a privately held biotechnology company focused on ... the Company has agreed to be acquired by sanofi-aventis (EURONEXT: ... will depend on the achievement of certain future milestones events ... fully realized. The closing of the transaction is expected to ...
Cached Biology Technology:Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 2Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement 3BioSpace Promotes the Northeast Corridor's Life Science Industry 2BioSpace Promotes the Northeast Corridor's Life Science Industry 3Sanofi-aventis to Acquire TargeGen, Inc. 2
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... the human body. Battles are won, lost or ... this stalemate—known as tumor dormancy—can last up to ... that is poorly understood. , A new ... Torquato, a Professor of Chemistry at Princeton University, ... and the switch to a malignant state. Published ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... mating systems, reproductive success reflects phenotypic variation. At ... that of body size and weapon morphology, as ... In a study published in the September issue ... Arizona University) and Jerry F. Husak (Oklahoma State ...
... step toward developing a new type of ultra-sensitive medical ... the skin to detect tiny gold nanorods injected into ... yielded images nearly 60 times brighter than conventional fluorescent ... of biological imaging to study the inner workings of ...
... "shooting stars" of their field. Many research scientists have been ... the blood into diseased organs and replace defective tissue. Such ... of certain muscle diseases. However, a study currently being conducted ... the cells are able to migrate into the muscle fibres, ...
Cached Biology News:Purdue's gold nanorods brighten future for medical imaging 2Research casts doubt on circulating stem cells 2Research casts doubt on circulating stem cells 3
... linear ion trap mass spectrometer enables high-throughput ... The LXQ linear ion trap mass spectrometer ... applications, delivering the fast cycle time and ... trap at an attractive price. The ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... short-term enriched housing for nonhuman primates and ... non-quarantine settings on a per diem basis. ... state-of-the-art social housing and nursery facilities. In ... CDC quarantine facilities. Primate housing and ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
Biology Products: